Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where D.S. Young is active.

Publication


Featured researches published by D.S. Young.


Cancer Research | 2005

Three unique antibodies demonstrate therapeutic effects against CD63, a novel target for cancer therapy

Susan E. Hahn; Victor Saldivia; Daad Sayegh; Huma Ahmad; Lisa M. Cechetto; Luis da Cruz; D.S. Young


Journal of Clinical Oncology | 2008

Human chimeric anti-CD44 antibody ARH460–16–2 binds leukemic cells and malignant plasma cells

T. Guillaume; N. Robillard; H. Avet-Loiseau; J. Delaunay; J. L. Harousseau; Susan Hahn; L. A. da Cruz; Daniel S. Pereira; D. B. Rubinstein; D.S. Young


Journal of Clinical Oncology | 2008

Clinical development of huARH460-16-2: A therapeutic antibody targeting the CD44 cancer stem cell antigen on high-incidence adenocarcinomas

Susan Hahn; L. A. da Cruz; Ashwani K. Gupta; B.C. Mak; L. Popp; Daniel S. Pereira; D. B. Rubinstein; D.S. Young


Ejc Supplements | 2008

521 POSTER A monoclonal antibody targeting the breast cancer stem cell marker melanoma-associated chondroitin sulfate proteoglycan improves survival and demonstrates anti-tumor activity in vivo

Ashwani K. Gupta; Alison L. Ferry; Mitra Amoozgar; Carlos Alexandre Vieira; Daad Sayegh; J. Menendez; N. Ceric; L.A.G. da Cruz; Daniel S. Pereira; D.S. Young


Ejc Supplements | 2008

517 POSTER A monoclonal antibody (AR36A36.11.1) with potent in vivo efficacy in multiple human cancer models targets CD59

B. Mak; F. McConkey; N. Feng; K. O'Reilly; S.W. Fung; M. Wang; S. Chau; S.E. Hahn; D.S. Pereira; D.S. Young


Ejc Supplements | 2008

371 POSTER Toxicology and pharmacokinetics of humanized AR47A6.4.2, the first unconjugated therapeutic monoclonal antibody targeting TROP-2

N. Chouinard; Susan Hahn; A.H.L. Truong; L. Popp; X. Wang; D. Sayegh; V. Harris; B.C. Mak; D.B. Rubinstein; D.S. Young


Ejc Supplements | 2008

538 POSTER ARH460-16-2, targeting the CD44 cancer stem cell marker, uses multiple mechanisms to achieve its therapeutic anti-cancer effects

L.A.G. da Cruz; K. O'Reilly; Fortunata McConkey; X.W. Wang; T. Antoshchenko; N. Aziz; Ashwani K. Gupta; Susan Hahn; Daniel S. Pereira; D.S. Young


Ejc Supplements | 2008

543 POSTER Location… location… location: hitting the functional epitope within the target is essential for anti-cancer antibody therapeutics

B.C. Mak; A.H.L. Truong; Ningping Feng; L.A.G. da Cruz; B.S. Mistry; Sui-Wah Fung; T. Perez; Susan Hahn; Daniel S. Pereira; D.S. Young


Molecular Cancer Therapeutics | 2007

Chimeric and humanized versions of the anti-CD44 monoclonal antibody ARH460-16-2 have potent anti-tumor efficacy in established models of human breast and metastatic liver cancer

Luis da Cruz; Ningping Feng; Terence Lee; Daad Sayegh; Baldwin Mak; Ming Wang; Mitra Amoozgar; Susan Hahn; Daniel Pereira; Helen Findlay; D.S. Young


ASCO Meeting Abstracts | 2007

Therapeutic monoclonal antibodies target phenotypically-differing human breast cancer

Susan Hahn; L. A. da Cruz; Daad Sayegh; Alison L. Ferry; K. O'Reilly; Daniel S. Pereira; D. B. Rubinstein; Helen P. Findlay; D.S. Young

Collaboration


Dive into the D.S. Young's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Daad Sayegh

University of Hong Kong

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Luis da Cruz

University of Hong Kong

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge